Vaxcyte, Inc. (PCVX) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Vaxcyte, Inc. (PCVX) posted $0 in revenue for fiscal 2025, with a net loss of $766.63M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Vaxcyte, Inc.
Vaxcyte, Inc. has grown revenue from $0 to $0 over the last 8 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Vaxcyte, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Vaxcyte, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-29.48M | $-50.27M | $-89.22M | $-100.08M | $-223.49M | $-402.27M | $-463.93M | $-766.63M |
| Net margin | — | — | — | — | — | — | — | — |
Source: Vaxcyte, Inc. SEC filings (10-K).
Vaxcyte, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 147.1% over 4 years (53M → 131.1M) — existing holders' stakes are being diluted.
Explore 8 years of Vaxcyte, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PCVX in your portfolio →
Vaxcyte, Inc. financial history by metric
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc. — frequently asked questions
What is Vaxcyte, Inc.'s revenue?
Vaxcyte, Inc. (PCVX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Vaxcyte, Inc. profitable?
No — PCVX reported a net loss of $-766.63M in fiscal 2025.
What is PCVX's P/E ratio?
Vaxcyte, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Vaxcyte, Inc. have?
As of fiscal year 2025, PCVX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Vaxcyte, Inc.'s market cap?
Vaxcyte, Inc. (PCVX) has a market capitalization of about $6.80B, based on the latest data in our nightly-refreshed cache.
When does Vaxcyte, Inc.'s fiscal year end?
PCVX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Vaxcyte, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.